Intra-Cellular Therapies Gestione
Gestione criteri di controllo 3/4
Intra-Cellular Therapies Il CEO è Sharon Mates, nominato in May2002, e ha un mandato di 22.5 anni. la retribuzione annua totale è $ 10.09M, composta da 8.8% di stipendio e 91.2% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 1.01% delle azioni della società, per un valore di $ 95.73M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 6.1 anni e 10.8 anni.
Informazioni chiave
Sharon Mates
Amministratore delegato
US$10.1m
Compenso totale
| Percentuale dello stipendio del CEO | 8.8% |
| Mandato del CEO | 22.5yrs |
| Proprietà del CEO | 1.0% |
| Durata media del management | 6.1yrs |
| Durata media del Consiglio di amministrazione | 10.8yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Revenues Tell The Story For Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) As Its Stock Soars 26%
Nov 07
Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Strong Position To Grow Its Business
Sep 22Peaking Back In On Intra-Cellular Therapies
Sep 04Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Just Released Its Second-Quarter Earnings: Here's What Analysts Think
Aug 10With Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) It Looks Like You'll Get What You Pay For
Jul 27Intra-Cellular Brightens MDD Outlook With Caplyta Success
Jun 19Intra-Cellular: More Upside Possible Even After Positive MDD Treatment Data
Apr 16Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) P/S Is On The Mark
Apr 09We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow
Mar 17Intra-Cellular Therapies Is On Fire
Mar 11Intra-Cellular Therapies: Buoyant Caplyta Sales And Upcoming MDD Data Support Short-Term 'Buy'
Feb 11Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) Price Is Out Of Tune With Revenues
Dec 24We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow
Nov 11Companies Like Intra-Cellular Therapies (NASDAQ:ITCI) Can Afford To Invest In Growth
Aug 07Here's Why We're Not At All Concerned With Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Situation
May 09After Leaping 31% Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Are Not Flying Under The Radar
Apr 17We're Not Very Worried About Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Rate
Jan 31Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Good Position To Deliver On Growth Plans
Oct 25Intra-Cellular Therapies: What Lies Ahead
Sep 20Intra-Cellular cut to Neutral at Goldman on trends for antipsychotic drug
Aug 22Intra-Cellular Therapies GAAP EPS of -$0.92 misses by $0.15, revenue of $55.6M beats by $6.98M
Aug 09We're Hopeful That Intra-Cellular Therapies (NASDAQ:ITCI) Will Use Its Cash Wisely
Jul 09Intra-Cellular Therapies: A Dramatic Story
Jun 18Companies Like Intra-Cellular Therapies (NASDAQ:ITCI) Are In A Position To Invest In Growth
Apr 03Intra-Cellular: Not Participating In A Bear Market
Mar 31Intra-Cellular; Long-Term To Own With A Few FDA Approvals And Ability To Expand
Mar 08Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$86m |
| Jun 30 2024 | n/a | n/a | -US$84m |
| Mar 31 2024 | n/a | n/a | -US$111m |
| Dec 31 2023 | US$10m | US$892k | -US$140m |
| Sep 30 2023 | n/a | n/a | -US$155m |
| Jun 30 2023 | n/a | n/a | -US$184m |
| Mar 31 2023 | n/a | n/a | -US$228m |
| Dec 31 2022 | US$9m | US$849k | -US$256m |
| Sep 30 2022 | n/a | n/a | -US$298m |
| Jun 30 2022 | n/a | n/a | -US$321m |
| Mar 31 2022 | n/a | n/a | -US$304m |
| Dec 31 2021 | US$7m | US$794k | -US$284m |
| Sep 30 2021 | n/a | n/a | -US$259m |
| Jun 30 2021 | n/a | n/a | -US$237m |
| Mar 31 2021 | n/a | n/a | -US$232m |
| Dec 31 2020 | US$5m | US$767k | -US$227m |
| Sep 30 2020 | n/a | n/a | -US$207m |
| Jun 30 2020 | n/a | n/a | -US$187m |
| Mar 31 2020 | n/a | n/a | -US$160m |
| Dec 31 2019 | US$5m | US$745k | -US$148m |
| Sep 30 2019 | n/a | n/a | -US$148m |
| Jun 30 2019 | n/a | n/a | -US$155m |
| Mar 31 2019 | n/a | n/a | -US$154m |
| Dec 31 2018 | US$4m | US$723k | -US$155m |
| Sep 30 2018 | n/a | n/a | -US$145m |
| Jun 30 2018 | n/a | n/a | -US$126m |
| Mar 31 2018 | n/a | n/a | -US$106m |
| Dec 31 2017 | US$5m | US$702k | -US$98m |
Compensazione vs Mercato: La retribuzione totale di Sharon ($USD 10.09M ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 7.92M ).
Compensazione vs guadagni: La retribuzione di Sharon è aumentata nonostante l'azienda non sia redditizia.
AMMINISTRATORE DELEGATO
Sharon Mates (71 yo)
22.5yrs
Mandato
US$10,086,413
Compensazione
Dr. Sharon Mates, Ph.D. co-founded Intra-Cellular Therapies, Inc. (a/k/a ITI) in May 2002 and was its President until March 19, 2024. She has been Chairman and Chief Executive Officer of Intra-Cellular The...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Co-Founder | 22.5yrs | US$10.09m | 1.01% $ 95.7m | |
| President | less than a year | US$3.53m | 0% $ 0 | |
| Executive VP & Chief Medical Officer | 6.3yrs | US$3.51m | 0.019% $ 1.8m | |
| EVP & Chief Commercial Officer | 6.1yrs | US$3.54m | 0.028% $ 2.7m | |
| Senior VP & Chief Scientific Officer | 9yrs | US$2.13m | Nessun dato | |
| Vice President of Corporate Communications & Investor Relations | 10.7yrs | US$1.38m | Nessun dato | |
| Senior VP & Chief Compliance Officer | 5.3yrs | Nessun dato | Nessun dato | |
| Senior Vice President | no data | Nessun dato | Nessun dato | |
| Senior VP & Head of Regulatory Affairs | 6.2yrs | Nessun dato | Nessun dato | |
| Senior VP of Market Access | 5.7yrs | Nessun dato | Nessun dato | |
| Senior VP & Head of Clinical Development | 2.6yrs | Nessun dato | Nessun dato |
6.1yrs
Durata media
61yo
Età media
Gestione esperta: Il team dirigenziale di ITCI è esperto e expertise (durata media dell'incarico 6.1 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Co-Founder | 11.3yrs | US$10.09m | 1.01% $ 95.7m | |
| Independent Director | 10.8yrs | US$470.51k | 0.11% $ 10.5m | |
| Lead Independent Director | 10.8yrs | US$507.58k | 0.011% $ 1.0m | |
| Independent Director | 11.3yrs | US$473.34k | 0.039% $ 3.7m | |
| Chairman of Medical Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of Medical Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of Medical Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of Medical Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of Medical Advisory Board | no data | Nessun dato | Nessun dato | |
| Independent Director | 2.6yrs | US$461.30k | 0.0015% $ 140.3k |
10.8yrs
Durata media
71yo
Età media
Consiglio di amministrazione esperto: Il consiglio di amministrazione di ITCI è composto da personale esperto e esperto (durata media dell'incarico 10.8 anni).